It’s the leading cause of disability due to pain and the most common form of arthritis, afflicting an estimated 237 million people worldwide. Osteoarthritis (OA) occurs as the cartilage on the end of bones wears down and most often affects the hands, knees, hips, and spine – though it can damage any joint in the body.
Treating the chronic pain patients experience is among the most enduring challenges in analgesic drug development. In this webinar, the speakers will examine:
- Osteoarthritis as a flexible model for development of new therapies
- Design of clinical trial protocols to address the special needs of the drug being studied
- Study design features that reduce placebo effects
- Typical efficacy scales in OA studies
- Common data analysis methods
Michael Kuss, Vice President, Strategic Development, Analgesia, Premier Research
Mr. Kuss is the Vice President, Strategic Development and focuses on building and reinforcing our depth in analgesia. He has been with the company since 2001 and has worked as an Executive Director, Clinical Trials Management and Senior Director, Analgesia and Rheumatology. Mr. Kuss’ focus at Premier Research includes projects in the Analgesia and Rheumatology area. He is responsible for working with clients to help develop clinical development plans, provide therapeutic expertise to internal and external clients, write protocols, manage study teams to conduct clinical trials, and participate in the preparation of clinical study reports.
Prior to joining Premier Research, Mr. Kuss worked for Pharmacia (formerly G.D. Searle) in various positions with the last being Director of Research and Development. He was responsible for clinical development of several COX-2 inhibitors (celecoxib, valdecoxib and parecoxib) and NSAIDs (oxaprozin, oxaprozin potassium, diclofenac/misoprostol) as part of the Arthritis and Inflammation team. Prior to G.D. Searle, Mr. Kuss worked as a Clinical Research Associate at Abbott Laboratories and as an Infectious Diseases Research Technologist and Clinical Instructor, Department of Medicine at Wright State University School of Medicine.
Mr. Kuss graduated from Wright State University in Dayton, Ohio with a BS in Medical Technology. He received a certification in Medical Technology from the American Society of Clinical Pathology. Mr. Kuss is a member of the American Pain Society (APS), International Association for the Study of Pain (IASP) and Drug Information Association. He is a frequent presenter at annual meetings of the American Pain Society and American College of Rheumatology annual meetings. He has presented at the IASP World Congress in Pain and at the IASP European Federation of IASP Chapters meetings. Mr. Kuss has presented at the DIA annual meeting and at several DIA sponsored symposia. He is an author on many publications and posters in the areas of analgesia, rheumatology and infectious disease.
Scott Millard, Executive Director, Strategic Development, Analgesia, Premier Research
Scott Millard has worked in the clinical research industry since 1991. Mr. Millard joined Premier Research in 1997. Since joining Premier, he has served in a variety of roles with increasing scope and responsibility inclusive of Senior Clinical Research Associate, Team Lead, Senior Manager, Project Manager, Senior Project Manager, Project Director, Senior Director and Executive Director. Mr. Millard served at a director level managing project managers and sponsor programs for more than 13 years specializing in Analgesia and Rheumatology.
Mr. Millard is currently Executive Director, Strategic Development, Analgesia. He serves as the principal strategist who advises, consults, plans and directs the design and strategy of new business opportunities and provides his expertise in the conduct of clinical trials. He is also responsible for developing strong relationships with existing and potential clients, clinical sites, and key opinion leaders.
Prior to joining Premier, Mr. Millard monitored for a large CRO and began his clinical research career in the Phase I arena at a large Phase I unit in Austin, first as a recruiter and then as an Instructor.
Mr. Millard has a Bachelor of Science degree from the University of Texas and was certified as a CCRA (Certified Clinical Research Associate) in 1995 by the ACRP. He is a member of The Association of Rheumatology Health Professionals and American Pain Society, with recurring affiliations with IASP, DIA and ACRP.Message Presenter
Who Should Attend?
VPs, Directors, Managers, Department Heads, Scientists and Researchers working within:
- Clinical Affairs
- Clinical R&D
- Clinical Research
- Clinical Pharmacology
- Clinical Operations
- Project Management
- Regulatory Affairs
- Medical Affairs
For pharmaceutical, biotechnology companies.
Premier Research is a leading CRO serving highly innovative biotech, pharmaceutical and medical device companies. The company has a wealth of experience in rare disease and pediatric research having managed about 100 projects in each area in the last five years alone. Its services include clinical research and regulatory outsourcing in the areas of analgesia; neurology; infectious, cardiovascular, and respiratory disease; dermatology; oncology; and medical devices.
Premier Research and operates in 84 countries. It employs 1,000+ clinical professionals dedicated first and foremost to fulfilling each customer’s requirements in a timely, accurate, and cost-effective manner. This includes a strong international network of monitors and project management professionals combined with regulatory, data management, statistical, scientific, and medical experts, and staff at its well-established network of dedicated clinical sites.